Rifampin reduces plasma concentrations and effects of zolpidem

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 6, 1997, Pages 629-634

  Villikka, Kirsti ^a   Kivistö, Kari T ^a   Luurila, Harri ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; MIDAZOLAM; PLACEBO; RIFAMPICIN; TRIAZOLAM; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPNOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TUBERCULOSIS;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FLICKER FUSION; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MENTAL PROCESSES; PYRIDINES; RIFAMPIN; SACCADES;

EID: 0031417357     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90082-5     Document Type: Article

References (15)

1. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142-53.
2. Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab Dispos 1995;23:1253-62.
3. Langtry H, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291-313.
4. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
5. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
6. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997;61:8-14.
7. Villikka K, Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol 1997;43:471-4.
8. Stanke F, Jourdil N, Bessard J, Bessard G, Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogenphosphorus detection. J Chromatogr B Biomed Appl 1996;675:43-51.
9. Griffiths AN, Marshall RW, Richens A. Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacol 1984;18:73S-82S.
10. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, et al. Metabolism of cyclosporin A; IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
11. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
12. Ohnhaus EE, Brockmeyer N, Dylewicz P, Habicht H. The effect of antipyrine and rifampicin on the metabolism of diazepam. Clin Pharmacol Ther 1987;42:148-56.
13. Brockmeyer NH, Mertins L, Klimek K, Goos M, Ohnhaus EE. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol 1990;28:387-93.
14. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31:198-214.
15. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients on carbamazepine or phenytoin. Epilepsia 1996;37:253-7.